You are here

Article Text

Article menu

Download PDFPDF

Paediatric rheumatology
Clinical case
Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
  1. Natalia Cabrera1,
  2. Agnes Duquesne,
  3. Marine Desjonquères1,
  4. Jean-Paul Larbre2,
  5. Jean-Christophe Lega3,4,
  6. Nicole Fabien5 and
  7. Alexandre Belot1,6
  1. 1Department of Pediatric Rheumatology, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Claude Bernard University Lyon 1, University of Lyon, Lyon, France
  2. 2Department of Rheumatology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Claude Bernard University Lyon 1, University of Lyon, Pierre-Bénite, France
  3. 3Department of Internal and Vascular Medicine, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Claude Bernard University Lyon 1, University of Lyon, Lyon, France
  4. 4Laboratoire de Biométrie et Biologie Evolutive, CNRS, Claude Bernard University Lyon 1, University of Lyon, Lyon, France
  5. 5Department of Immunology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France
  6. 6INSERM U1111
  1. Correspondence to Dr Alexandre Belot; alexandre.belot{at}chu-lyon.fr

Abstract

Arthritis is one of the main manifestations of mixed connective tissue disease (MCTD) and overlap syndrome in children and can be responsible for functional disability. We report on 2 children with arthritis that were dramatically improved by a treatment with interleukin-6 (IL-6) blockers in the context of connective tissue disease. However, in both cases, other systemic autoimmune symptoms were not modified by the treatment and autoantibodies tend to increase, suggesting a differential effect of IL-6 inhibition on articular inflammation and systemic autoimmunity.

  • Systemic Lupus Erythematosus
  • Autoimmune Diseases
  • Cytokines
  • Dermatomyositis
  • Juvenile Idiopathic Arthritis

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/rmdopen-2016-000271

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text